Charles River Laboratories International
VC Fund
Wilmington, United States
Charles River Laboratories International is a VC fund in Wilmington focused on Biotechnology and Health Care. Charles River Laboratories International, Inc. provides solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. Segments The company has two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which includes Phase Iclinical services. RESEARCH MODELS AND SERVICES (RMS) The company supplies research models to the drug development industry. With approximately 150 different strains the company engages in the production and sale of research models, principally genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist customers in supporting the use of research models in drug development. With multiple facilities located on three continents (North America, Europe and Asia (Japan)), the company maintains production centers, including a total of approximately 180 barrier rooms or isolator facilities located near its customers. RMS segment comprises Research Models, Research Model Services, and other related products and services
- Total investments:
- 14
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Charles River Laboratories International invests in
Stages Charles River Laboratories International invests in
Countries Charles River Laboratories International invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $20M–$31M
- Series B
- $12M–$103M
Investment Focus
Industry
- Biotechnology 5 (36%)
- Health Care 2 (14%)
- Life Science 2 (14%)
- Therapeutics 2 (14%)
- Medical 1 (7%)
Stage
- Series A 3 (21%)
- Series B 3 (21%)
- Funding Round 2 (14%)
- Seed 1 (7%)
- Series C 1 (7%)
Country
- United States 4 (29%)
- Canada 1 (7%)
- France 1 (7%)
- Ireland 1 (7%)
- United Kingdom 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anja Tessarz
Scientific Specialist Viral Clearance
|
Scientific Specialist Viral Clearance | Total investments: 0 | Find email | |
Bill Jefferson
Business Development Director - Safety Assessment
|
Business Development Director - Safety Assessment | Total investments: 0 | Find email | |
Chris Lowrie
Senior Director, Lab Sciences
|
Senior Director, Lab Sciences | Total investments: 0 | Find email | |
|
Gina Mullane
Sr. Vice President Client Experience and Chief Marketing Officer
|
Sr. Vice President Client Experience and Chief Marketing Officer | Total investments: 0 | Find email | |
Greg Mason
Sr. Director, Global Category Procurement, Lab Operations
|
Sr. Director, Global Category Procurement, Lab Operations | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $32.1M / Series C / Jan 07, 2025 | ||
| Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $18M / Seed / Jun 18, 2024 | ||
| Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $12M / Seed / Dec 06, 2023 | ||
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $20M / Series A / Jun 27, 2023 | |
| IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs. The platform's low-cost, highly scalable Intelligent Vector Solutions are intended to alleviate the vector supply bottleneck and increase access to life-saving treatments for patients.Intelligent VectorSolutions from iVexSol are revolutionizing the production of LVVs, which are gene delivery vehicles that are a critical raw material in the manufacture of life-changing cell and gene therapies (CGTs). The technology platform employs banks of vector-producing cells to produce LVV in significantly greater quantities than current approaches while allowing for the rapid scale-out required for global demand, all within a smaller manufacturing footprint. These advancements allow for shorter clinical development timelines, lower costs, and, ultimately, greater global access for patients who are waiting for these transformative medicines. | $23.8M / Series A / Jan 26, 2023 | ||
| Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $31M / Series A / Oct 04, 2022 | ||
|
Vernal Biosciences
|
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M / Series A / Jun 02, 2022 | |
| Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $11.5M / Series B / May 19, 2022 | ||
| PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M / Series B / Nov 09, 2021 | ||
| PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $17.4M / Series B / Nov 09, 2021 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Charles River Laboratories International invest in?
Charles River Laboratories International invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Charles River Laboratories International invest in?
Charles River Laboratories International typically joins rounds of $20M–$31M at Series A and $12M–$103M at Series B. These are whole funding-round sizes, not Charles River Laboratories International's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Charles River Laboratories International took part in.
How do I contact Charles River Laboratories International?
Public channels for Charles River Laboratories International include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Charles River Laboratories International?
The team at Charles River Laboratories International includes Anja Tessarz (Scientific Specialist Viral Clearance), Bill Jefferson (Business Development Director - Safety Assessment) and Chris Lowrie (Senior Director, Lab Sciences), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
